“Tackling the Tumor Microenvironment & Further Arming the Immune System” was moderated by Louise Chen and Pete Stavropoulos. The panel featured John Hayslip, CMO of I-Mab Biopharma and Matt Robinson, CTO of Immunome, Inc.

• I-Mab Biopharma shared its excitement surrounding its Lemzoparlimab program, noting its recent approval from China CDE to initiate phase 3 registrational study of Lemzoparlimab in combination with Azacidine in higher-risk Myelodysplastic Syndrome.

• The discussion with Immunome touched on the ability of its platform technology to identify potentially novel oncology targets/therapeutic agents, its lead oncology candidate IMM-ONC-01 (anti-IL-38 antibody), and the rationale for its possible use in various cancers, the upcoming P1b data readout for its COVID-19 antibody cocktail in 4Q22, and potential monetization of its discoveries by partnering programs.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare